GenesisCare has confirmed plans to expand its cancer care centre in Guildford with a new Systemic Anti-Cancer Therapy service, scheduled to open in winter 2026.
The development will see a full fit-out and expansion into currently unused space within the purpose-built Guildford facility, which opened in March 2024.
The new suite will become the eighth SACT centre in the organisation’s UK network.
GenesisCare is still in the process of appointing contractors for the full fit-out and expansion of the Guildford facility.
The Surrey SACT unit will provide a range of treatments including chemotherapy, immunotherapy and cellular therapy within a purpose-built clinical environment.
It will also function as a research centre, offering eligible patients access to innovative drug regimens not widely available elsewhere.
How the centre is part of the provider’s oncology goals
GenesisCare has delivered cancer services in Surrey for more than 13 years and relocated to its current standalone oncology centre in Guildford in 2024.
The site already provides advanced radiotherapy, including MR Linac technology, alongside diagnostic imaging, theranostics, wellbeing services and exercise medicine facilities.
The addition of SACT services is intended to complete the centre’s oncology offering, bringing systemic therapies together with existing modalities under one roof.
With SACT services now spanning sites in Bristol, Oxford, Milton Keynes, Windsor, Guildford, Maidstone, Cambridge and the forthcoming centre in Royal Tunbridge Wells, GenesisCare said the expansion would help reduce travel burdens for patients undergoing treatment across the region.
The provider added that further UK expansion plans for its cancer services are expected to be announced in due course.
“I witness every day the difference that timely access to expert, specialist treatment can make. The opening of this new GenesisCare SACT service marks an exciting and important milestone for our community,” said Dr Tony Dhillon, Consultant Medical Oncologist and Senior Lecturer in Oncology.